GENB Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About GENB Interactive Breakdown Better Bets vs. GENB Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Generate Biomedicines (GENB)

    Market Price (8/25/2026): $17.58 | Market Cap: $2.3 BilSector: Health Care | Industry: Biotechnology

    Generate Biomedicines (GENB)

    Market Price (8/25/2026): $17.58
    Market Cap: $2.3 Bil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -19%

    Megatrend and thematic drivers
    Megatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -11%, 3Y Excs Rtn is -47%

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -244 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -751%

    Significant share based compensation
    SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 77%

    Not cash flow generative
    CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -740%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -757%

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15%

    Significant short interest
    Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 15.25

    Key risks
    GENB key risks include [1] a precarious financial position due to its high valuation and limited cash runway, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -19%
    1 Megatrend and thematic drivers
    Megatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -11%, 3Y Excs Rtn is -47%
    3 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -244 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -751%
    4 Significant share based compensation
    SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 77%
    5 Not cash flow generative
    CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -740%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -757%
    6 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -15%
    7 Significant short interest
    Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 15.25
    8 Key risks
    GENB key risks include [1] a precarious financial position due to its high valuation and limited cash runway, Show more.

    GENB in ETFs

    Weight = GENB's share of each fund

    VTI0.00%
    IWM0.01%
    IWO0.02%
    VTWO0.01%
    SCHA0.01%
    IWN0.01%
    ONEQ0.01%
    SCHB0.00%

    Valuation & Metrics

    FYE: 12/31GENB [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$32.5 Mil—
    FY 2026 Sales$29.7 Mil—
    FY 2027 Sales$23.8 Mil—
    FY 2026 Sales Growth-8.6%—
    FY 2027 Sales Growth-19.7%13.0%
    EARNINGS
    LTM Net Income (GAAP) [3]$-222.8 Mil—
    FY 2026 Net Income (Non-GAAP)$-115.0 Mil—
    FY 2027 Net Income (Non-GAAP)$-113.6 Mil—
    FY 2027 Net Income Growth—19.2%
    FY 2026 EPS (Non-GAAP)$-2.27—
    FY 2027 EPS (Non-GAAP)$-2.29—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S76.01.8
    FY 2027 P/S94.6—
    FY 2026 P/E—8.4
    FY 2027 P/E——

    [1] GENB forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 8/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    GENBS&P 500
    REVENUE GROWTHFAIR
    Rev LTM ($ Bil)0.0
    Rev Chg Q�9.3%
    Rev Chg LTM�8.4%
    PROFITABILITYVERY POOR
    Op Inc LTM ($ Bil)-0.2
    CFO LTM ($ Bil)-0.2
    Net Inc LTM ($ Bil)-0.2
    Op Mgn LTM-751.2%18.4%
    CFO/Rev LTM-739.6%21.8%
    Net Inc Mgn-685.9%13.0%
    VALUATIONVERY HIGH
    P/S69.43.3
    P/CFO-9.415.6
    P/FCF-9.220.3
    P/E-10.123.2
    STABILITYVERY GOOD
    Debt/Equity0.030.19
    Cash/Assets0.810.06

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Pipeline Programs179142023Link
    Number of Strategic Collaborations49242024Link
    Number of Patent Applications100+10252023Link
    Number of Employees31212312025Link
    Protein Structures in Platform Dataset1600009142023Link
    Genetic Sequences in Platform Dataset1900000009142023Link
    High-Resolution Cryo-EM Maps Produced>50012312025Link

    Price Chart

    No Events

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 8/24/2026

    Generate Biomedicines (GENB) stock has gained about 40% since 4/30/2026 because of the following key factors:

    1. Advancement of Key Clinical Pipeline Programs. Generate Biomedicines made significant progress across its clinical pipeline during the period. Its lead asset, GB-0895, continued to advance in global Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials for severe asthma. Additionally, GB-4362 received FDA Fast Track designation for the prevention and reduction of enfortumab vedotin-induced toxicity in urothelial cancer, with the first cohort in its Phase 1 study enrolled and dosed. Furthermore, the company initiated recruitment for a Phase 1 trial of GB-5267, a CAR T therapy for ovarian cancer, with the first patient expected to be dosed in 2026.

    2. Validation of AI-Powered Generative Biology Platform Through Strategic Collaboration. The company's generative biology platform received external validation when Novartis advanced an AI-designed biologic into its preclinical pipeline, marking a key milestone for an AI-engineered therapeutic reaching this stage. This demonstrated the potential of Generate Biomedicines' core technology in drug discovery and development.

    Show more
    Updated on 8/24/2026

    Generate Biomedicines (GENB) stock has gained about 40% since 4/30/2026 because of the following key factors:

    1. Advancement of Key Clinical Pipeline Programs. Generate Biomedicines made significant progress across its clinical pipeline during the period. Its lead asset, GB-0895, continued to advance in global Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials for severe asthma. Additionally, GB-4362 received FDA Fast Track designation for the prevention and reduction of enfortumab vedotin-induced toxicity in urothelial cancer, with the first cohort in its Phase 1 study enrolled and dosed. Furthermore, the company initiated recruitment for a Phase 1 trial of GB-5267, a CAR T therapy for ovarian cancer, with the first patient expected to be dosed in 2026.

    2. Validation of AI-Powered Generative Biology Platform Through Strategic Collaboration. The company's generative biology platform received external validation when Novartis advanced an AI-designed biologic into its preclinical pipeline, marking a key milestone for an AI-engineered therapeutic reaching this stage. This demonstrated the potential of Generate Biomedicines' core technology in drug discovery and development.

    3. Strong Financial Position and Extended Cash Runway. Generate Biomedicines reported a robust cash, cash equivalents, and marketable securities balance of $457.4 million as of June 30, 2026, the end of fiscal Q2 2026. The company indicated that this capital is sufficient to fund its current operating plan into the first half of 2028, providing significant financial stability and reducing near-term financing concerns for its extensive research and development efforts.

    4. Favorable Analyst Sentiment and Price Targets. Generate Biomedicines maintained a "Moderate Buy" consensus rating from eight analysts. Analysts issued an average 12-month price target of $25.40, implying a substantial upside of approximately 43.34% from the stock's price of $17.72 as of August 24, 2026. Notable upgrades included HC Wainwright increasing its price target from $16.00 to $25.00 in May 2026, and Morgan Stanley raising its target from $20.00 to $22.00, reflecting confidence in the company's future prospects.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    null
    null

    Market Drivers

    4/30/2026 to 8/24/2026
    ReturnCorrelation
    GENB40.3% 
    Market (SPY)6.2%21.0%
    Sector (XLV)19.7%19.3%

    Fundamental Drivers

    null
    null

    Market Drivers

    1/31/2026 to 8/24/2026
    ReturnCorrelation
    GENB  
    Market (SPY)10.6%21.0%
    Sector (XLV)13.4%20.5%

    Fundamental Drivers

    null
    null

    Market Drivers

    7/31/2025 to 8/24/2026
    ReturnCorrelation
    GENB  
    Market (SPY)21.8%21.0%
    Sector (XLV)35.7%20.5%

    Fundamental Drivers

    null
    null

    Market Drivers

    7/31/2023 to 8/24/2026
    ReturnCorrelation
    GENB  
    Market (SPY)72.7%21.0%
    Sector (XLV)36.3%20.5%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    GENB Return-----27%27%
    Peers Return-42%-52%10%-55%12%69%-74%
    S&P 500 Return27%-19%24%23%16%12%104%

    Monthly Win Rates [3]
    GENB Win Rate-----57% 
    Peers Win Rate36%37%48%35%55%60% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    GENB Max Drawdown------ 
    Peers Max Drawdown-68%-66%-64%-67%-55%-40% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: SDGR, RXRX, ABCL, RLAY, DNA.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 8/24/2026 (YTD)

    How Low Can It Go

    GENB has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

    EventXLVS&P 500
    2025 US Tariff Shock
      % Loss-11.7%-18.8%
      % Gain to Breakeven13.3%23.1%
      Time to Breakeven142 days79 days
    2022 Inflation Shock & Fed Tightening
      % Loss-13.8%-24.5%
      % Gain to Breakeven15.9%32.4%
      Time to Breakeven166 days427 days
    2020 COVID-19 Crash
      % Loss-27.9%-33.7%
      % Gain to Breakeven38.8%50.9%
      Time to Breakeven77 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-15.0%-19.2%
      % Gain to Breakeven17.6%23.8%
      Time to Breakeven191 days105 days
    2015-2016 China Devaluation / Global Growth Scare
      % Loss-15.9%-12.2%
      % Gain to Breakeven18.9%13.9%
      Time to Breakeven165 days62 days
    2011 US Debt Ceiling Crisis & European Contagion
      % Loss-15.8%-17.9%
      % Gain to Breakeven18.8%21.8%
      Time to Breakeven153 days123 days

    Compare to SDGR, RXRX, ABCL, RLAY, DNA

    In The Past

    State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    GENB has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

    EventXLVS&P 500
    2020 COVID-19 Crash
      % Loss-27.9%-33.7%
      % Gain to Breakeven38.8%50.9%
      Time to Breakeven77 days140 days
    2008-2009 Global Financial Crisis
      % Loss-37.9%-53.4%
      % Gain to Breakeven61.1%114.4%
      Time to Breakeven767 days1085 days

    Compare to SDGR, RXRX, ABCL, RLAY, DNA

    In The Past

    State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Generate Biomedicines (GENB)

    Generate Biomedicines (GENB) is a clinical-stage generative biology company that leverages artificial intelligence to transform drug design and development. The company's core asset is its proprietary "Generate Platform," an AI-driven system that integrates advanced computational models with scalable biohardware. This platform operates through a continuous design-build-test-learn loop, enabling the creation of novel therapeutics, including the de novo design of proteins, by generating and rapidly verifying biological hypotheses at scale.

    The company's pipeline includes several computationally engineered drug candidates. Its most advanced product, GB-0895, is a long-acting anti-TSLP monoclonal antibody currently enrolling patients in pivotal Phase 3 clinical trials for severe asthma, with a targeted Q26W (every six months) dosing regimen to improve patient adherence. GB-0895 is also undergoing evaluation in a Phase 1b clinical trial for moderate-to-severe chronic obstructive pulmonary disease (COPD). Additionally, Generate Biomedicines expects to advance two oncology candidates, GB-4362 (an antibody designed to neutralize free MMAE as an adjunctive therapy for ADCs) and GB-5267 (an armored, MUC16-directed CAR-T cell therapy for solid tumors), into Phase 1 trials in 2026.

    Generate Biomedicines aims to address substantial unmet medical needs across a range of therapeutic areas, serving patients with conditions like severe asthma, COPD, and various solid tumors. Beyond its internal pipeline, the Generate Platform is also the foundation for confidential drug development programs in collaboration with major pharmaceutical partners such as Amgen and Novartis, demonstrating the platform's broad applicability and potential for generating innovative medicines across diverse disease indications.

    AI Analysis | Feedback

    Generate Biomedicines is like **Moderna, but for AI-designed proteins and drugs instead of mRNA.**

    Generate Biomedicines is like An OpenAI for drug discovery, leveraging generative AI to design novel medicines.

    AI Analysis | Feedback

    Generate Biomedicines (GENB) offers the following major products:

    • Generate Platform: A proprietary AI-driven generative biology platform designed to program biology and generate optimal therapeutics across various modalities.
    • GB-0895: An investigational long-acting anti-TSLP monoclonal antibody currently in pivotal Phase 3 clinical trials for severe asthma and Phase 1b for COPD.
    • GB-4362: A monoclonal antibody developed as an adjunctive therapy to neutralize free MMAE, used with antibody-drug conjugate molecules.
    • GB-5267: An armored, MUC16-directed CAR-T cell therapy candidate being developed for solid tumors, specifically targeting platinum-resistant ovarian cancer.

    AI Analysis | Feedback

    ```html

    Generate Biomedicines (GENB) primarily sells to other companies through collaborations. The major customer companies mentioned in the provided description are:

    • Amgen Inc. (AMGN)
    • Novartis Pharma AG (NVS)
    ```

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Generate Biomedicines (GENB) faces several key risks inherent to its business model as a clinical-stage generative biology company:

    1. Clinical Trial Failure and Regulatory Approval Challenges: The company's success heavily relies on the successful outcome of its ongoing and planned clinical trials for product candidates such as GB-0895 (in pivotal Phase 3 trials for severe asthma and Phase 1b for COPD) and other oncology candidates (expected to advance into Phase 1 in 2026). Failure of these trials to demonstrate safety and efficacy, or an inability to obtain necessary regulatory approvals from agencies like the FDA, would significantly impede the company's ability to commercialize its products and generate revenue.
    2. Dependence on the Efficacy of its Proprietary Generate Platform: Generate Biomedicines' core strategy is built around its proprietary "Generate Platform," an AI-driven system for drug design and development. The platform's ability to consistently generate optimal therapeutics, learn generalizable design principles, and integrate with advanced experimental biohardware is fundamental to the company's pipeline. Any limitations, inefficiencies, or failures in the platform's ability to produce viable and differentiated molecular solutions could undermine the company's long-term success and ability to develop new product candidates.
    3. Intense Competition in the Biotechnology and Pharmaceutical Industry: The fields of severe asthma, COPD, and oncology are highly competitive, with established pharmaceutical companies and other biotechnology firms developing and marketing treatments. Even if Generate Biomedicines' product candidates receive regulatory approval, they will face significant competition from existing therapies, including biologics, and new entrants. This competition could impact market adoption, pricing, and overall commercial success of the company's therapeutic offerings.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Generate Biomedicines (symbol: GENB) has the following addressable market sizes for its main products:

    • GB-0895 for severe asthma:
      • The global severe asthma treatment market is valued at approximately USD 24.30 billion in 2025 and is projected to reach USD 39.96 billion by 2035.
      • The U.S. severe asthma therapeutics market size was estimated at USD 13.00 billion in 2024 and is projected to reach USD 19.20 billion by 2033.
    • GB-0895 for moderate-to-severe COPD:
      • The global chronic obstructive pulmonary disease (COPD) treatment market size is expected to be valued at USD 21.04 billion in 2025 and is anticipated to reach around USD 34.59 billion by 2035.
      • North America generated more than 42% of the revenue share in 2025 for the COPD treatment market.
    • GB-4362 (adjunctive therapy to ADC molecules with an MMAE payload): null
    • GB-5267 (armored, MUC16-directed CAR-T cell therapy for solid tumors, initially targeting platinum-resistant ovarian cancer): null

    AI Analysis | Feedback

    Expected Drivers of Future Revenue Growth for Generate Biomedicines (GENB)

    • Advancement and Potential Approval of GB-0895 for Severe Asthma: Generate Biomedicines' lead product candidate, GB-0895, an investigational long-acting anti-TSLP monoclonal antibody, is currently enrolling patients in two pivotal global Phase 3 clinical trials (SOLAIRIA-1 and SOLAIRIA-2) for severe asthma, with the first patient dosed in January 2026. Successful progression through these trials and eventual market approval within the next 2-3 years would be a significant driver of revenue growth, especially given its potential for a Q26W dosing regimen and ultra-high binding affinity, which could address adherence challenges with existing therapies.
    • Expansion of GB-0895 into Chronic Obstructive Pulmonary Disease (COPD): In parallel with its severe asthma program, Generate Biomedicines is conducting a Phase 1b clinical trial for GB-0895 in moderate-to-severe COPD, with data expected in 2026. Positive results from this trial and subsequent advancement into later-stage development would open up a new and substantial market for GB-0895, significantly broadening its revenue potential beyond severe asthma.
    • Progression of Oncology Product Candidates into Clinical Trials: The company expects to advance two additional computationally generated oncology product candidates, GB-4362 and GB-5267, into Phase 1 clinical trials in 2026, following the clearance of their Investigational New Drug (IND) applications in December 2025. While direct product revenue from these programs is further out, their successful initiation and early clinical data will validate the Generate Platform and could trigger milestone payments from potential future partnerships or collaborations, contributing to revenue growth.
    • Milestone Payments from Strategic Collaborations: Generate Biomedicines has established confidential programs with Amgen Inc. and Novartis Pharma AG, which leverage its Generate Platform. As these collaborative programs advance through preclinical and clinical development stages, they are expected to trigger milestone payments, providing a source of non-product revenue growth over the next 2-3 years.

    AI Analysis | Feedback

    Inbound Investments

    • Generate Biomedicines has confidential programs under development in collaboration with Amgen Inc. and Novartis Pharma AG.

    Capital Expenditures

    • Generate Biomedicines has invested in scalable biohardware systems, encompassing DNA assembly, rapid protein production, and high-throughput, multiplexed assay miniaturization.
    • The company has established a cryogenic electron microscopy ("Cryo-EM") core, which generated over 500 high-resolution maps in 2025.
    • These capital investments are focused on reducing the cost and time per assay data point, thereby strengthening the link between generative models and real-world biological verification.

    Peer Outperformance in Biotechnology

    null
    Share of Biotechnology constituents that GENB has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    —
    insufficient peer history
    3Y
    —
    insufficient peer history
    5Y
    —
    insufficient peer history
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is GENB's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 7 11.5%85.0%132.2% CAH 400% · MCK 348% · COR 189%
    Health Care Services 20 20.9%46.0%3.9% HIMS 314% · RDNT 146% · DGX 80%
    Managed Health Care 8 32.1%-1.6%3.5% OSCR 143% · HQY 64% · ELV 16%
    Health Care Facilities 24 7.9%-2.8%-17.5% THC 278% · NHC 257% · ENSG 125%
    Health Care Equipment 50 -2.9%-6.1%-21.0% POCI 10987% · UFPT 367% · GKOS 253%
    Health Care Supplies 12 34.1%-12.7%-32.6% LNTH 301% · HAE 81% · MMSI 30%
    Pharmaceuticals 63 4.3%6.4%-37.4% LQDA 2532% · INDV 1260% · ETON 1176%
    Life Sciences Tools & Services 108 -3.6%-28.4%-72.7% SNWV 1827% · ELMD 249% · MEDP 243%
    Health Care Technology 21 -21.8%-55.6%-74.4% SPOK 125% · HSTM -1% · VEEV -24%
    Biotechnology ← 365 7.1%-26.0%-78.7% BRTX 106500% · CELZ 1629% · DNTH 1519%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    MRNAModerna54.9115.5%371.0%
    AMLXAmylyx Pharmaceuticals4.278.0%215.8%
    EMATEvolution Metals & Technologies2.650.9%-80.2%
    ASSTStrive1.249.5%33.7%
    PURRHyperliquid Strategies1.348.8%198.9%
    MRVIMaravai LifeSciences1.248.4%159.4%
    WEAVWeave Communications0.631.8%-4.0%
    BMNRBitMine Immersion Technologies13.328.9%-11.1%
    TEMTempus AI11.828.1%12.1%
    XXITwenty One Capital4.127.5%-28.0%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    AEHRAehr Test Systems3.0-33.8%377.6%
    AXTIAXT3.5-31.9%300.0%
    AEVAAeva Technologies1.0-30.7%23.9%
    AAOIApplied Optoelectronics8.2-30.5%208.7%
    FNFabrinet15.1-29.6%-7.5%
    WOLFWolfspeed1.0-29.2%42.2%
    RGNXRegenxbio0.4-28.9%-44.1%
    AMRCAmeresco1.1-26.4%-28.4%
    FEIMFrequency Electronics0.6-26.0%8.4%
    MXLMaxLinear5.7-25.9%260.2%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MRNAModerna54.9156.9%371.0%
    HTFLHeartFlow4.3108.1%72.2%
    AMLXAmylyx Pharmaceuticals4.2107.2%215.8%
    ABCLAbCellera Biologics3.299.8%210.2%
    LIFEEthos Technologies1.898.5%4353.1%
    OMEROmeros1.497.3%12.5%
    TEAMAtlassian44.797.2%5.7%
    NIQNIQ Global Intelligence5.778.4%16.3%
    PURRHyperliquid Strategies1.371.9%198.9%
    ASSTStrive1.271.7%33.7%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    SIONSionna Therapeutics0.3-87.8%-86.4%
    TENXTenax Therapeutics0.1-87.3%-84.8%
    MPLTMapLight Therapeutics0.5-68.9%-35.3%
    EYPTEyePoint0.4-60.0%-73.3%
    TDUPThredUp0.4-50.7%-56.0%
    AHCOAdaptHealth0.8-47.7%-43.5%
    KLCKinderCare Learning Companies0.3-47.1%-39.6%
    REZIResideo Technologies2.9-44.2%-45.1%
    LMBLimbach0.5-42.7%-46.4%
    UTIUniversal Technical Institute1.2-41.7%-15.7%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    GENBSDGRRXRXABCLRLAYDNAMedian
    NameGenerate.Schrodin.Recursio.AbCeller.Relay Th.Ginkgo B. 
    Mkt Price17.7218.773.2510.6119.766.7814.16
    Mkt Cap2.31.41.73.24.00.42.0
    Rev LTM3225954661011260
    Op Inc LTM-244-153-544-211-310-288-266
    FCF LTM-246-130-354-120-212-175-194
    FCF 3Y Avg--100-365-143-253-265-253
    CFO LTM-240-127-350-95-212-170-191
    CFO 3Y Avg--93-355-89-251-238-238

    Growth & Margins

    GENBSDGRRXRXABCLRLAYDNAMedian
    NameGenerate.Schrodin.Recursio.AbCeller.Relay Th.Ginkgo B. 
    Rev Chg LTM-8.9%-16.4%101.3%23.9%-46.8%8.9%
    Rev Chg 3Y Avg-10.3%4.6%7.8%1,195.1%-25.4%7.8%
    Rev Chg Q-7.5%-61.8%-76.3%-48.3%-48.5%-48.5%
    QoQ Delta Rev Chg LTM-1.6%-18.0%-16.5%-3.1%-14.5%-14.5%
    Op Inc Chg LTM-20.5%16.3%20.0%9.5%-1.9%16.3%
    Op Inc Chg 3Y Avg-1.0%-30.6%-42.7%6.1%34.4%1.0%
    Op Mgn LTM-751.2%-59.2%-1,008.6%-318.7%-2,999.4%-257.7%-535.0%
    Op Mgn 3Y Avg--81.0%-942.9%-632.4%-2,721.8%-258.1%-632.4%
    QoQ Delta Op Mgn LTM-5.4%-118.3%-68.9%-222.8%-40.4%-68.9%
    CFO/Rev LTM-739.6%-49.0%-649.8%-143.5%-2,050.3%-152.2%-401.0%
    CFO/Rev 3Y Avg--42.4%-641.8%-221.9%-1,992.1%-143.6%-221.9%
    FCF/Rev LTM-756.9%-50.3%-656.8%-180.8%-2,050.3%-156.3%-418.8%
    FCF/Rev 3Y Avg--45.4%-660.7%-373.0%-1,997.0%-158.2%-373.0%

    Valuation

    GENBSDGRRXRXABCLRLAYDNAMedian
    NameGenerate.Schrodin.Recursio.AbCeller.Relay Th.Ginkgo B. 
    Mkt Cap2.31.41.73.24.00.42.0
    P/S70.05.432.149.0387.33.840.5
    P/Op Inc-9.3-9.1-3.2-15.4-12.9-1.5-9.2
    P/EBIT-9.9-9.1-3.3-15.4-12.9-1.4-9.5
    P/E-10.2-25.8-3.3-19.7-14.0-1.4-12.1
    P/CFO-9.5-11.1-4.9-34.1-18.9-2.5-10.3
    Total Yield-9.8%-3.9%-30.0%-5.1%-7.1%-69.1%-8.5%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg--7.6%-18.6%-12.7%-27.5%-41.1%-18.6%
    D/E0.00.10.00.00.01.00.0
    Net D/E-0.2-0.2-0.3-0.1-0.20.2-0.2

    Returns

    GENBSDGRRXRXABCLRLAYDNAMedian
    NameGenerate.Schrodin.Recursio.AbCeller.Relay Th.Ginkgo B. 
    1M Rtn32.2%25.4%9.8%99.8%7.2%-7.9%17.6%
    3M Rtn22.0%41.1%8.0%104.0%46.0%-19.4%31.5%
    6M Rtn40.1%67.3%-4.7%250.2%121.0%-23.5%53.7%
    12M Rtn40.1%-7.6%-34.2%141.7%435.5%-46.0%16.2%
    3Y Rtn40.1%-46.6%-61.9%92.6%92.4%-89.9%-3.3%
    1M Excs Rtn29.0%22.1%6.5%96.6%3.9%-11.1%14.3%
    3M Excs Rtn19.6%38.7%5.6%101.6%43.6%-21.8%29.1%
    6M Excs Rtn28.2%55.4%-16.6%238.2%109.1%-35.4%41.8%
    12M Excs Rtn19.9%-24.3%-52.1%126.6%459.3%-62.5%-2.2%
    3Y Excs Rtn-35.0%-119.7%-138.1%17.8%15.8%-164.6%-77.4%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q1
    Period End6/30/20263/31/2026
    Filing Date8/6/20265/7/2026
    Key Financials Quarterly  
    Total Revenue67
    Ebitda-64-58
    Operating Income-72-64
    Net Income-67-61
    EPS-0.52-1.07
    Key Financials TTM  
    Total Revenue TTM32-
    Ebitda TTM-216-
    Operating Income TTM-244-
    Net Income TTM-223-
    Growth Rates Quarterly  
    Total Revenue Growth--
    EBITDA Growth--
    Operating Income Growth--
    Net Income Growth--
    Margins Quarterly  
    EBITDA Margin-1010.8%-806.1%
    Operating Income Margin-1134.2%-887.5%
    Net Income Margin-1065.2%-850.6%
    Cash & Debt  
    Total Cash457517
    Total Debt6366
    Net Debt / (Cash)-395-451
    Cash Flows Quarterly  
    FCF from Operations-58-80
    Cash Flows TTM  
    FCF from Operations TTM-240-
    Returns to Shareholders Quarterly  
    Dividends00
    Share Repurchases-0-0
    Return on Invested Capital (ROIC) Quarterly  
    ROIC-33.1%-32.0%
    Return on Invested Capital (ROIC) TTM  
    ROIC TTM-28.2%-

    Segment Financials

    Revenue by Segment
    $ Mil20252024
    Field of generative biology by using machine learning for drug discovery and development through the3220
    Total3220


    Net Income by Segment
    $ Mil20252024
    Field of generative biology by using machine learning for drug discovery and development through the-203-174
    Total-203-174


    Price Behavior

    null
    GENB Betas & Captures as of 7/31/2026

     1M2M3M6M1Y3Y
    Beta1.201.651.481.12-0.51-0.50
    Up Beta5.313.802.23-0.33-1.610.41
    Down Beta-0.023.641.89-1.88-0.70-2.87
    Up Capture-103%46%136%71%32%3%
    Bmk +ve Days11223567138427
    Stock +ve Days51629505050
    Down Capture175%4%103%69%46%26%
    Bmk -ve Days11212859114326
    Stock -ve Days172734565656

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GENB
    GENB40.3%84.2%1.20-
    Sector ETF (XLV)29.3%16.0%1.4120.5%
    Equity (SPY)21.2%12.9%1.2321.0%
    Gold (GLD)39.0%28.8%1.143.6%
    Commodities (DBC)40.9%20.2%1.58-6.9%
    Real Estate (VNQ)13.9%13.8%0.701.4%
    Bitcoin (BTCUSD)-30.4%44.2%-0.6910.3%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GENB
    GENB7.0%84.2%1.20-
    Sector ETF (XLV)6.9%15.1%0.2720.5%
    Equity (SPY)12.8%17.2%0.5721.0%
    Gold (GLD)20.6%18.6%0.903.6%
    Commodities (DBC)10.2%19.6%0.41-6.9%
    Real Estate (VNQ)2.4%18.9%0.021.4%
    Bitcoin (BTCUSD)11.2%52.8%0.4010.3%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with GENB
    GENB3.4%84.2%1.20-
    Sector ETF (XLV)10.7%16.7%0.5220.5%
    Equity (SPY)15.1%17.9%0.7221.0%
    Gold (GLD)12.9%16.3%0.653.6%
    Commodities (DBC)7.8%18.1%0.35-6.9%
    Real Estate (VNQ)5.0%20.7%0.201.4%
    Bitcoin (BTCUSD)63.1%66.2%1.0310.3%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date7312026
    Short Interest: Shares Quantity7.3 Mil
    Short Interest: % Change Since 71520264.2%
    Average Daily Volume0.5 Mil
    Days-to-Cover Short Interest15.2 days
    Basic Shares Quantity128.2 Mil
    Short % of Basic Shares5.7%

    Earnings Returns History

    Updated 8/17/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/6/2026-4.1%4.1% 
    5/7/2026-11.2%6.0%-15.9%
    SUMMARY STATS   
    # Positive020
    # Negative201
    Median Positive 5.1% 
    Median Negative-7.7% -15.9%
    Max Positive 6.0% 
    Max Negative-11.2% -15.9%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/6/2026-4.1%4.1% 
    5/7/2026-11.2%6.0%-15.9%
    SUMMARY STATS   
    # Positive020
    # Negative201
    Median Positive 5.1% 
    Median Negative-7.7% -15.9%
    Max Positive 6.0% 
    Max Negative-11.2% -15.9%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/06/202610-Q
    03/31/202605/07/202610-Q
    12/31/202502/27/2026424B4
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/06/202610-Q
    03/31/202605/07/202610-Q
    12/31/202502/27/2026424B4

    Insider Activity

    Updated 4/26/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Nally, MichaelChief Executive OfficerDirectBuy306202612.0020,000240,0006,872,484Form
    2Grous, BethChief People OfficerSpouseBuy302202616.003004,8004,800Form
    3Silvers, JasonPresident & CFOdaughterBuy302202616.001,00016,0008,000Form
    4Silvers, JasonPresident & CFOsonBuy302202616.001,00016,00016,000Form
    5Afeyan, Noubar Flagship Pioneering Fund VII, L.P.Buy302202616.001,562,50025,000,000244,235,584Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Nally, MichaelChief Executive OfficerDirectBuy306202612.0020,000240,0006,872,484Form
    2Grous, BethChief People OfficerSpouseBuy302202616.003004,8004,800Form
    3Silvers, JasonPresident & CFOdaughterBuy302202616.001,00016,0008,000Form
    4Silvers, JasonPresident & CFOsonBuy302202616.001,00016,00016,000Form
    5Afeyan, Noubar Flagship Pioneering Fund VII, L.P.Buy302202616.001,562,50025,000,000244,235,584Form
    6Afeyan, Noubar FPN II, L.P.Buy302202616.001,562,50025,000,00069,444,032Form
    7Afeyan, Noubar Pioneering Medicines 02, LLCBuy302202616.001,562,50025,000,00025,000,000Form
    8Mendillo, Jane L DirectBuy302202616.001,50024,00024,000Form
    9Afeyan, Noubar Flagship Pioneering Fund VII, L.P.Buy302202616.001,562,50025,000,000244,235,584Form
    10Afeyan, Noubar FPN II, L.P.Buy302202616.001,562,50025,000,00069,444,032Form
    11Afeyan, Noubar Pioneering Medicines 02, LLCBuy302202616.001,562,50025,000,00025,000,000Form

    Investor Activity (13F)

    Updated Aug 25, 2026
    13F holdings as of Mar 31, 2026 (Q1 2026)

    Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Flagship Pioneering, LLC$783.4 Mil67.4%7New13F
    ARCH Venture Management, LLC$24.3 Mil3.6%10New13F
    Davern Capital Partners, LP$7.4 Mil2.0%17New13F
    Harvard Management Co Inc$13.9 Mil0.8%17New13F
    Nvidia Corp$10.4 Mil0.1%7New13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Flagship Pioneering, LLC$783.4 Mil67.4%7New13F
    ARCH Venture Management, LLC$24.3 Mil3.6%10New13F
    Harvard Management Co Inc$13.9 Mil0.8%17New13F
    Nvidia Corp$10.4 Mil0.1%7New13F
    Davern Capital Partners, LP$7.4 Mil2.0%17New13F
    Active Manager
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Flagship Pioneering, LLC$783.4 Mil67.4%7New13F
    ARCH Venture Management, LLC$24.3 Mil3.6%10New13F
    Harvard Management Co Inc$13.9 Mil0.8%17New13F
    Nvidia Corp$10.4 Mil0.1%7New13F
    Davern Capital Partners, LP$7.4 Mil2.0%17New13F

    Generate Biomedicines — Investor Video Playlist

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 8/24/2026